Ozempic: Boon for Diabetes Patients, Burden for the Health System?

Canada has a new distinction. Our country has been crowned the second-largest Ozempic user in the world. Most of us know about Ozempic’s class of drugs, GLP-1s, for weight loss, courtesy of testimonials from celebrities like Oprah Winfrey. But the reality is Ozempic, or semaglutide, was first developed for type 2 diabetes, a serious disease that can lead to blindness, kidney failure, amputations and heart attacks. 

New data from the Canadian Institute for Health Information shows that our health system has gone from spending about $13 million a year on Ozempic to over $800 million a year — an increase of nearly 6,000%. CIHI’s pharmaceutical data tool allows users to explore this dramatic rise in spending and see how drug costs are shifting across the country. It’s now the fastest growing drug expense for the public purse. Sticker shock for some, but as host Avis Favaro discovers, according to diabetes specialist and University of Calgary professor Dr. David Lau, paying upfront for this miracle drug will be well worth it in the long run.

This episode is available in English only.

Episode transcripts can be found on our podcast web page.

Learn more about the Canadian Institute for Health Information (CIHI).

Say hello on LinkedIn, Facebook and Instagram, or subscribe to our YouTube channel. You can also stay up to date on the latest news and upcoming releases with our monthly newsletter.

Vous préférez les balados français? Voyez le Balado d’information sur la santé au Canada.